bioaffinitytech.com (BIAF) - Cash Money per Share

bioAffinity Technologies (BIAF) relies on competent management in the field of early cancer diagnostics, which requires capital expenditures for expansion. Partnerships with laboratories enable the implementation of AI tests for detecting lung tumors. Optimized express delivery of kits ensures stability for medical institutions. Cash per share visualizes the company's liquidity, while the 1.40 level reflects the current magnitude of this reserve.
Comprehensive metric breakdowns and analytics for bioAffinity Technologies, Inc. (BIAF)

The operational resilience of bioAffinity Technologies (BIAF) is reflected in the dynamics of its free liquidity per share. This metric calculates the actual volume of cash attributable to a single security following trading sessions. Such a calculation allows for an assessment of the actual capital reserve, excluding market revaluations at peaks. For the owner of the unique CyPath Lung test, these reserves confirm the ability to maintain pricing power. A high level of liquidity guarantees the financial autonomy of the business.